Welcome to our dedicated page for Serina Therapeutics news (Ticker: ser), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Serina Therapeutics, Inc. (symbol: SER) is a forward-thinking, clinical-stage biotechnology company dedicated to pioneering treatments for neurological diseases and pain. At the heart of Serina's innovation is its proprietary POZ Platform delivery technology, which is specifically designed to provide unparalleled control over drug loading and the precision of drug release rates. This technology aims to enhance the efficacy of challenging small molecules and addresses the conventional limitations posed by polyethylene glycol (PEG) and other biocompatible polymers.
Serina Therapeutics is actively developing a robust pipeline of wholly-owned drug product candidates, showcasing the company’s commitment to advancing healthcare solutions. The POZ Platform holds the promise of transforming therapeutic delivery by enabling more effective and manageable treatments for patients with chronic conditions.
Recently, the company has made significant strides in its clinical trials and research projects, reflecting its potential in the biotechnology landscape. With a focus on innovation, Serina Therapeutics is forging partnerships and collaborations to bolster its research and development efforts.
Financially, Serina Therapeutics is positioned as a key player in the biotech sector, attracting attention from investors and stakeholders. For the latest updates and insights on the company's performance and developments, interested parties are encouraged to reach out to the Investor Contact, Steven Ledger, Interim Chief Executive Officer, at (256) 327-9630 or via email at investor.relations@serinatherapeutics.com.
Serina Therapeutics (NYSE American: SER) has appointed Dr. Jay Venkatesan to its Board of Directors. Dr. Venkatesan brings extensive experience in biotechnology investment and company building, most recently serving as Chairman, President, and CEO of Angion Biomedica until its 2023 merger with Elicio Therapeutics.
His notable achievements include co-founding Alpine Immune Sciences, which was acquired by Vertex Pharmaceuticals for $4.9 billion in May 2024. Dr. Venkatesan's background includes founding Ayer Capital, a healthcare investment fund, and holding positions at Brookside Capital and McKinsey & Co.
As part of this transition, Serina's co-founder Dr. Milton Harris will become Director Emeritus and Chair of the company's Scientific Advisory Board (SAB), continuing to provide guidance for the company's research and development efforts.
Serina Therapeutics (NYSE: SER) has successfully closed the second $5 million tranche of its $10 million equity financing with JuvVentures (UK) . This funding will support the advancement of SER-252, a treatment for advanced Parkinson's disease, into Phase 1 clinical trials in the second half of 2025.
The transaction involved issuing 500,000 shares at $10 per share, representing a 113% premium to the January 31, 2025 closing price. Additionally, warrants for up to 755,728 shares at $18.00 per share were issued to JuvVentures. The company's POZ Platform™ drug optimization technology enables SER-252 (POZ-apomorphine) to provide continuous dopaminergic stimulation through an innovative drug delivery system.
Serina Therapeutics (NYSE American: SER) has announced the sale of its UniverXome subsidiary, completed on December 23, 2024. The transaction eliminates $11.2 million in subsidiary-level debt, resulting in a debt-free balance sheet for Serina entering 2025.
The UniverXome subsidiary was established before Serina's reverse merger with AgeX Therapeutics in March 2024 to hold legacy assets. This strategic move aligns with Serina's focus on advancing SER-252, their lead candidate for advanced Parkinson's disease, into clinical development. The company aims to explore their POZ Platform™ technology across multiple therapeutic applications, including small molecules, lipid nanoparticles (LNPs), and antibody-drug conjugates (ADCs).
Serina Therapeutics (NYSE American: SER) has announced the appointment of Karen J. Wilson to its Board of Directors. Wilson brings over 30 years of leadership experience in life sciences, currently serving on the boards of Connect Biopharma Holdings, Elicio Therapeutics, and LAVA Therapeutics.
Wilson previously held senior finance positions at Jazz Pharmaceuticals, including Senior Vice President of Finance and Principal Accounting Officer. Her prior experience includes senior finance roles at PDL BioPharma, ViroLogic, and Novare Surgical Systems, as well as consulting and auditing at Deloitte & Touche LLP. She is a Certified Public Accountant with a B.S. in Business from UC Berkeley.
The company also announced the departure of Steven Mintz from its Board of Directors, who helped guide Serina's transition from private to public company.
Serina Therapeutics (NYSE: SER) has announced a upcoming webinar presentation focused on continuous drug delivery solutions for Parkinson's disease. The event, titled 'Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond,' will feature CEO Steven A. Ledger and is scheduled for December 18, 2024, at 8:30 AM Pacific/11:30 AM Eastern.
The presentation will address continuous dopaminergic stimulation (CDS), which has demonstrated effectiveness in reducing motor complications in advanced Parkinson's patients. The discussion will compare Serina's IND candidate's target product profile with current standard treatments in providing CDS. The event will be hosted by Tribe Public's Managing Member John F. Heerdink, Jr., and will include a Q&A session.
Serina Therapeutics (NYSE American: SER) announced that their Chief Development Officer, Randall Moreadith, MD, PhD, will present at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston. The presentation focuses on their proprietary POZ-lipid technology, which shows promising results in improving lipid nanoparticle (LNP) formulations.
Key findings demonstrate that POZ-lipid did not trigger IgM or IgG antibody responses after repeated administration in animal testing. This contrasts with conventional PEG-lipids, which produced strong antibody responses. The absence of immune response to POZ-lipid suggests potential for developing safer LNP formulations, particularly significant given that anti-PEG antibody responses have been linked to hypersensitivity reactions in mRNA-based vaccine recipients.
Serina Therapeutics (NYSE American: SER) has secured a $10 million equity financing from JuvVentures (UK) to advance SER-252 (POZ-apomorphine) into Phase 1 clinical trials for advanced Parkinson's disease patients in H2 2025. The financing involves issuing one million shares at $10 per share, representing a 120% premium to the November 26 closing price. The funding will be delivered in two $5 million tranches, with the first received on November 27, 2024, and the second due by January 31, 2025.
Serina Therapeutics (NYSE American: SER) reported Q3 2024 financial results and business updates. The company's revenue was $14,000 from NIH grants, down from $29,000 in Q3 2023. Operating expenses increased to $5.3 million from $1.5 million year-over-year. Despite reporting net income of $1.4 million ($0.16 per basic share), the company faces substantial going concern issues with only $3.2 million in cash as of September 30, 2024. Key highlights include a partnership with Enable Injections for their lead candidate SER-252, targeting advanced Parkinson's disease through their POZ Platform™ technology.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to three new non-executive employees. The grants, totaling 60,500 shares of common stock, were made on November 6, 2024, with exercise prices matching the closing stock price on that date. These options were approved as employment inducement awards under NYSE American's Company Guide Section 711(a). The options will vest over three years, with one-third vesting after the first year and the remaining two-thirds vesting in 24 monthly installments, contingent on continued employment.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company, announced its participation in the 14th Annual Injectables Summit in Boston, MA. The company's Chief Development Officer, Randall Moreadith, MD, PhD, will present alongside Enable Injections' Chief Commercial Officer Matthew Huddleston.
Their joint presentation, titled 'Patient-enabled Therapy for Advanced Parkinson's Disease', will focus on the collaboration between Serina's SER-252 and Enable Injections' enFuse Wearable Drug Delivery Platform. This partnership aims to provide advanced Parkinson's Disease patients with life-changing therapeutics through comfortable and convenient delivery methods.
Serina Therapeutics is known for developing its proprietary POZ Platform™ drug delivery technology, which is likely to be a key component in this collaborative effort to improve patient care and treatment outcomes.
FAQ
What is the current stock price of Serina Therapeutics (ser)?
What is the market cap of Serina Therapeutics (ser)?
What is Serina Therapeutics, Inc.?
What does the POZ Platform delivery technology do?
What makes Serina's POZ Platform unique?
What are the main therapeutic areas Serina Therapeutics focuses on?
How can I contact Serina Therapeutics for investor inquiries?
Are there any recent achievements by Serina Therapeutics?
What is the financial outlook for Serina Therapeutics?
How does Serina Therapeutics plan to advance its research and development efforts?
